T-Rex 2X Inverse NVIDIA Daily Target ETF NVDQ
Nov 4, 2026, 2:09 PM EST
- YTD
- -40.77%
- 1 year
- -36.66%
- Market cap
- 15.79M
- Revenue (ttm)
- 83.87M
- Profit margin
- -66.61%
- Shares out
- 57.82M
- Forward P/E
- -16.32
- YTD return
- -40.77%
- 1-year return
- -36.66%
- Volume
- 10.90M
- Avg volume
- 6.94M
- Open
- 10.01
- Previous close
- 9.71
- Day's range
- 9.70 – 10.23
- 52-week range
- 7.16 – 20.57
- Beta
- 1.32
- Analysts
- Hold
- Price target
- 12.00 (+20.6%)
2Y -61.59 (-86.02%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 7.75
- Price / book
- 7.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 2.20%
- Free cash flow
- -29.88M
- Total cash
- 49.59M
- Total debt
- 9.59M
- Return on equity
- -48.87%
- Short % of float
- 0.00%
- 50-day average
- 11.69
- 200-day average
- 9.34
Analyst view
Consensus: hold
- Target (low)
- 11.75
- Target (mean)
- 12.00
- Target (high)
- 13.00
- Strong buy0
- Buy2
- Hold8
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 12, 2017 | RBC Capital | down | — | Sector Perform |
| Jul 12, 2017 | JMP Securities | down | — | Market Perform |
| Jul 9, 2017 | Canaccord Genuity | down | — | Hold |
| Jun 18, 2017 | Craig-Hallum | down | — | Hold |
| Jan 10, 2017 | William Blair | down | — | Market Perform |
| Jul 27, 2016 | Feltl & Co. | up | — | Strong Buy |
About T-Rex 2X Inverse NVIDIA Daily Target ETF
Novadaq Technologies Inc. develops, manufactures, and markets fluorescence imaging products for use by surgeons in the operating room and other clinical settings in the United States and internationally. The company offers SPY Elite, a fluorescence imaging system that enables surgeons performing open procedures, such as breast and other reconstruction, gastrointestinal, and cardiothoracic surgery, to visualize microvascular blood flow and perfusion in tissue intraoperatively. It also provides PINPOINT endoscopic fluorescence imaging systems; LUNA fluorescence angiography system that provides clinicians with real-time visualization of tissue perfusion in patients; and Dermacell, a decellularized regenerative human tissue matrix that is used in breast reconstruction surgeries, as well as in the treatment of diabetic foot and venous stasis ulcers, and chronic non-healing wounds. Novadaq Technologies Inc. has alliances with Intuitive Surgical, Inc.; LifeNet Health; MAQUET Getinge Group; and Arthrex, Inc. Novadaq Technologies Inc. was founded in 2000 and is headquartered in Mississauga, Canada.
- Sector
- Healthcare
- Industry
- Medical Laboratories & Research
- Country
- Canada
- Website
- novadaq.com
News
Your note
Sign in to keep a note on NVDQ — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Primecap Management Company | 9.91% | 5,728,149 | 67.19M | Jun 29, 2017 |
| JP Morgan Chase & Company | 9.18% | 5,308,769 | 62.27M | Jun 29, 2017 |
| ArrowMark Colorado Holdings LLC | 8.64% | 4,991,937 | 58.56M | Jun 29, 2017 |
| Riverbridge Partners LLC | 5.47% | 3,164,568 | 37.12M | Jun 29, 2017 |
| Janus Henderson Group PLC | 4.82% | 2,786,932 | 32.69M | Jun 29, 2017 |
| Sand Grove Capital Management LLP | 3.99% | 2,305,000 | 27.04M | Jun 29, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Primecap Odyssey Aggressive Growth Fund | 9.78% | 5,655,749 | 43.55M | Mar 30, 2017 |
| Janus Henderson Triton Fund | 4.85% | 2,802,215 | 21.58M | Mar 30, 2017 |
| Legg Mason Clearbridge Small Cap Growth Fd | 3.97% | 2,294,353 | 17.67M | Mar 30, 2017 |
| Variable Insurance Products Fund-Growth Portfolio | 2.63% | 1,518,400 | 10.95M | May 30, 2017 |
| Vanguard Explorer Fund, Inc. | 2.59% | 1,497,291 | 9.78M | Jan 30, 2017 |
| Janus Henderson Venture Fund | 2.34% | 1,355,208 | 10.44M | Mar 30, 2017 |